Lisdexamfetamine
10 Mg — Capsule
Also known as:
Vyvanse
Lisdexamfetamine 10 Mg Capsule
Lisdexamfetamine 20 Mg Capsule
Lisdexamfetamine 30 Mg Capsule
Lisdexamfetamine 40 Mg Capsule
Lisdexamfetamine 50 Mg Capsule
Lisdexamfetamine 60 Mg Capsule
Lisdexamfetamine 70 Mg Capsule
Lisdexamfetamine 10 Mg Chewable Tablet
Lisdexamfetamine 20 Mg Chewable Tablet
Lisdexamfetamine 30 Mg Chewable Tablet
Lisdexamfetamine 40 Mg Chewable Tablet
Lisdexamfetamine 50 Mg Chewable Tablet
Lisdexamfetamine 60 Mg Chewable Tablet
Coverage by Insurer
Informational only — Coverage rules change frequently; verify tier placement and restrictions with your plan or pharmacy before acting.
Blue Cross Blue Shield Federal
2 plans| Plan | Tier | Prior Auth | Step Therapy | Quantity Limit | Restrictions |
|---|---|---|---|---|---|
|
BCBS Federal Basic Option 2026
via Vyvanse |
Tier 3 - Non-Preferred Brand | ✓ | — | — | PA |
|
BCBS Federal Standard Option 2026
via Vyvanse |
Tier 3 - Non-Preferred Brand | ✓ | — | — | PA |
Blue Cross Blue Shield of NC
5 plans| Plan | Tier | Prior Auth | Step Therapy | Quantity Limit | Restrictions |
|---|---|---|---|---|---|
|
BCBSNC Blue Local 2026
via Vyvanse |
Tier 2 - Medium Cost Generic/Brand | — | — | ✓ | QL |
|
BCBSNC Blue Care 2026
via Vyvanse |
Tier 2 - Medium Cost Generic/Brand | — | — | ✓ | QL |
|
BCBSNC Blue Value 2026
via Vyvanse |
Tier 2 - Medium Cost Generic/Brand | — | — | ✓ | QL |
|
BCBSNC Blue Advantage 2026
via Vyvanse |
Tier 2 - Medium Cost Generic/Brand | — | — | ✓ | QL |
|
BCBSNC Blue Home with UNC Health Alliance 2026
via Vyvanse |
Tier 2 - Medium Cost Generic/Brand | — | — | ✓ | QL |
Cigna
1 planNC Medicaid PDL
2 plansNC State Health Plan
3 plans| Plan | Tier | Prior Auth | Step Therapy | Quantity Limit | Restrictions |
|---|---|---|---|---|---|
|
NC State Health Plan - 80/20 Plus PPO 2026
via Vyvanse |
Not Covered | — | — | — | None |
|
NC State Health Plan - 70/30 Standard PPO 2026
via Vyvanse |
Not Covered | — | — | — | None |
|
NC State Health Plan - HDHP 2026
via Vyvanse |
Not Covered | — | — | — | None |